The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL VIROLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-05-06
DOI
10.1002/jmv.25985
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- Coronavirus puts drug repurposing on the fast track
- (2020) Charlotte Harrison NATURE BIOTECHNOLOGY
- Another Decade, Another Coronavirus
- (2020) Stanley Perlman NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- From SARS to MERS, Thrusting Coronaviruses into the Spotlight
- (2019) Zhiqi Song et al. Viruses-Basel
- Narrative review of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: updates and implications for practice
- (2019) Abbas Al Mutair et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis
- (2016) Alaa Badawi et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Nelfinavir and Nelfinavir Analogs Block Site-2 Protease Cleavage to Inhibit Castration-Resistant Prostate Cancer
- (2015) Min Guan et al. Scientific Reports
- Virus and Cell Fusion Mechanisms
- (2014) Benjamin Podbilewicz Annual Review of Cell and Developmental Biology
- Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy
- (2014) Joell J. Gills et al. Autophagy
- Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis
- (2010) Ansgar Brüning et al. CANCER BIOLOGY & THERAPY
- A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry
- (2010) A. Shulla et al. JOURNAL OF VIROLOGY
- Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2
- (2010) S. Matsuyama et al. JOURNAL OF VIROLOGY
- Virus Cell-to-Cell Transmission
- (2010) W. Mothes et al. JOURNAL OF VIROLOGY
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
- (2009) Garrett M. Morris et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started